Treatment of Dyspareunia with Botulinum Neurotoxin Type A: Clinical Improvement and Influence of Patients' Characteristics. [PDF]
Int J Environ Res Public Health, 2021 Tarazona-Motes M +5 more
europepmc +1 more source
Review of combined intravesical and urethral botulinum neurotoxin type A injection in patients with neurogenic lower urinary tract dysfunction. [PDF]
Tzu Chi Med JLiu HH, Hsu CK, Young WL, Wu SY.
europepmc +1 more source
Cell-Penetrating Botulinum Neurotoxin Type A With Improved Cellular Uptake and Therapeutic Index. [PDF]
Front Bioeng Biotechnol, 2022 Wei X, Li L, Wu Y, Liu J.
europepmc +1 more source
Pupillographic Investigations after Botulinum Toxin Therapy
, 2003 Systemic side effects after therapeutic use of botulinum neurotoxin type A (BoNT/A) presynaptically inhibiting acetylcholine release have been ...
Esther Bulang, MD; Rolf Fötzsch, MD; Holger Lüdtke, MD
core
BDNF rs6265 polymorphism is not associated with the occurrence of overactive bladder and its response to intradetrusor injection of botulinum neurotoxin type A in female patients. [PDF]
Sci RepCiećwież SM +7 more
europepmc +1 more source
Elucidating the crystal structure of botulinum neurotoxin type A: a personal remembrance. [PDF]
J Neural Transm (Vienna)Lacy DB.
europepmc +1 more source
Characterization of Neurotoxin Mutants inClostridium botulinumType [PDF]
Clinical Infectious Diseases, 1997 E A, Johnson +3 more
openaire +2 more sources
Dysphagia After Cosmetic Submandibular Gland Botulinum Neurotoxin Type A Injection: A Case Report. [PDF]
Healthcare (Basel)Yang S, Yi YG.
europepmc +1 more source
Clinical and Neurophysiological Effects of Botulinum Neurotoxin Type A in Chronic Migraine. [PDF]
Toxins (Basel), 2021 Valente M +4 more
europepmc +1 more source
Immunological Considerations of Polysorbate as an Excipient in Botulinum Neurotoxin Type A Formulations: A Narrative Review. [PDF]
Toxins (Basel)Martin MU +5 more
europepmc +1 more source